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Summary Vasoactive drugs have a variety of effects upon splanchnic and hepatic haemodynamics which may
alter tumour blood flow and potentiate the delivery of a chemotherapeutic drug to hepatic tumour.
We have investigated the effects of vasopressin infusion on hepatic tumour blood flow in an experimental
model of liver tumour.
Hepatic tumour was induced by the intraportal inoculation of HSN sarcoma cells. Hepatic and splanchnic
blood flow was determined using a dual reference microsphere technique before and after an intravenous
infusion of vasopressin at a dose of 0.1 mU kg-'min-' for 10 min.
There was a significant increase in systemic arterial blood pressure associated with a rise in portal venous
inflow (P<0.01, Wilcoxen Signed rank Test) and a significant fall in hepatic arterial flow (P<0.05). The
tumour: liver blood flow ratio was significantly increased by vasopressin infusion (P<0.02). Vasopressin
infusion decreases hepatic arterial flow and increases tumour blood flow which may potentiate the delivery of
a regionally delivered chemotherapeutic drug to hepatic tumour.
Up to 60% of patients with colorectal cancer develop liver
metastases which are rarely resectable surgically (Rapoport &
Burleson, 1970). Systemic or regional chemotherapy is often
used to treat these patients, but is relatively ineffective partic-
ularly with respect to survival. The poor response to chemo-
therapy may be a reflection of the hypovascular nature of
most liver metastases which prevents access of therapeutic
drug to the tumour (Kemeny et al., 1987; Taylor et al., 1979).
Vasoactive drugs have a variety of effects on splanchnic
and hepatic haemodynamics which may alter tumour blood
flow and potentiate the delivery of a chemotherapeutic drug
to liver tumour (Mattson et al., 1978). Vasopressin, a potent
vasoconstrictor, reduces portal pressure in portal hyperten-
sive patients and is used clinically to control variceal
haemorrhage. However, the effects of vasopressin on hepatic
haemodynamics varies with its rate of infusion. At low rates
of infusion vasopressin has been demonstrated to decrease
portal venous flow but increase hepatic arterial flow, whilst
at higher rates of infusion these effects are reversed (Jenkins
et al., 1984; 1985).
We have developed a model of liver metastases in the rat
using the HSN sarcoma. Our previous studies have demon-
strated that tumour development in this model is associated
with a decrease in portal venous inflow with no change in
hepatic arterial flow. The tumours are supplied entirely from
the hepatic artery, are histologically hypovascular compared
to the surrounding liver parenchyma and do not show
arteriosystemic shunting (Hemingway et al., 1989). The mod-
el therefore displays many of the characteristics of human
colorectal liver metastases and may prove useful in eval-
uating whether vasoactive drugs can potentiate delivery of
cytotoxic drug to liver tumour. In this study we have inves-
tigated the effects of a systemic infusion of vasopressin on
hepatic and splanchnic haemodynamics in rats with overt
liver tumour.
Methods
Tumour induction
HSN sarcoma cells were grown in Dulbecco's modified
Eagles Medium (Sigma, UK) supplemented with 10% foetal
calf serum at 37°C in a humidified atmosphere of 5% CO2 in
an incubator. Metastases were induced by the intraportal
inoculation of 106 HSN sarcoma cells, trypsinised from a
confluent monolayer, in Lister rats. Our previous studies
have shown that discrete liver metastases are constantly pre-
sent 3 weeks after the inoculation of these tumour cells.
Hepatic haemodynamics
Organ blood flow, before and after the infusion of vaso-
pressin, were measured using a dual microsphere reference
method.
Effects ofvasopressin
One hundred thousand 57 Co microspheres (Nentrac, Du-
pont, Germany) suspended in normal saline with 0.01%
Tween were injected over 20 s via a cannula (Portex, Hythe,
UK, outside diameter 0.61 mm) screened into position in the
left ventricle using a Siemens Image Intensifier (Siemens,
Germany). A reference sample of blood was withdrawn from
the right femoral artery starting 10 s before the injection of
microspheres and continuing for 40 s after the injection. The
withdrawal rate was constant at 1 ml per min. Arterial blood
pressure was monitored using a strain gauge transducer and
Gould pen recorder (Gould Medical, Lutterworth, UK)
attached to a cannula in the left femoral artery.
In ten rats vasopressin was infused via the right femoral
vein at a dose of 0.1 mU kg- 'min-', for 10min at a con-
stant rate of 0.2 ml per min. Control rats received similar
infusion of the same volume of isotonic saline (n = 5). At the
end of the infusion ofvasopressin or saline a second injection
of 51 Cr microspheres, was given via the ventricular cannula
and a second reference sample obtained as described pre-
viously. Five minutes later the animals were killed, the liver
and splanchnic organs removed, weighed and the radioac-
tivity counted on a gamma well counter (Packard, UK)
together with the reference samples. The counts were cor-
rected for spillover between the two channels. Results were
rejected if renal blood flow between the right and left kidneys
differed by greater than 10% or if any sample contained less
than 400 particles, since this indicates inadequate ventricular
mixing of macrospheres.
Organ blood flow was calculated using the method of
McDevitt and Nies (1976):
Organ blood flow = organ counts x reference
reference counts withdrawal
rate
Hepatic arterial flow was calculated from the counts in the
liver. Portal venous inflow was calculated from counts in the
Correspondence: T.G. Cooke, University Department of Surgery,
Royal Infirmary, Glasgow G31 2ER, UK.
Received 19 December 1990; and in revised form 2 April 1991.
Br. J. Cancer (1991), 64, 212-214 '." Macmillan Press Ltd., 1991VASOPRESSIN AND HEPATIC TUMOUR BLOOD FLOW 213
splanchnic organs draining into the portal vein. Hepatosplan-
chnic flow is the sum of hepatic arterial and portal venous
inflows. Hepatic tumour was dissected from the surrounding
normal liver, both weighed and counted separately, and the
results expressed as a ratio of tumour:liver blood flow in
ml min-' g-' tissue.
Statistical differences before and after infusion of vasopres-
sin or saline were evaluated using the non-parametric Wil-
coxen signed rank test.
Results
The mean hepatic replacement by tumour was 27.12%. The
haemodynamic effects of vasopressin infusion were as fol-
lows.
Changes in bloodflow
Hepatic arterial flow (Figure 1) was significantly decreased
from 3.28 (1.82) ml min-' (Median (interquartile range)) to
1.65 (2.37) mlmin-' after vasopressin infusion (P<0.05).
However, portal venous inflow (Figure 2) increased
significantly from 2.12 (1.93) to 5.38 (7.08) ml min-'
(P<0.01). The infusion of vasopressin had no significant
effect on hepatosplanchnic flow 5.54 (2.44) mlmin-' to 7.52
(5.01) mlmin-'.
Tumour:liverflow
The tumour:liver blood flow ratio rose significantly from a
median of 0.38: one before, to 1.49: one following the
infusion of vasopressin. This represents an effective doubling of tumour blood flow (P =0.02) (Figure 3).
Arterial bloodpressure
Arterial blood pressure rose from 95.5 (29.5)mmHg to
113mmHg after vasopressin infusion (P<0.01).
Effects ofsaline infusion
Saline infusion had no significant effect on hepatic arterial,
portal venous or hepatosplanchnic flow. The tumour:liver
blood flow ratio and systemic blood pressure were also
unchanged (Table I).
Discussion
The efficacy of regional chemotherapy may be improved by pharmacological manipulation of hepatic blood flow with
vasoactive agents which by altering intrahepatic haemo-
dynamics may potentiate the blood flow to liver tumour
Pre-infusion Post-infusion
Vasopressin 0.1 mU kg-1 min1
Figure 1 Change in hepatic arterial flow with vasopressin in-
fusion (P<0.02 Wilcoxen signed rank test). Horizontal bar =
median.
14
12
10 -
7 8-
C
E
6-
4.
2-
0n
Pre-infusion Post-infusion
Vasopressin 0.1 mU kg-' min-'
Figure 2 Change in portal venous inflow with vasopressin
infusion (P< 0.01 Wilcoxen signed rank test). Horizontal bar =
median.
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Figure 3 Change in the tumour:liver blood flow ratio after
vasopressin infusion (P = 0.02 - Wilcoxen signed rank test).
Horizontal bar = median.
Table I Change in hepatic arterial flow, portal venous inflow, hepatosplanchnic flow, tumour:liver blood flow ratio and systemic blood pressure after saline infusion (0.2 ml min ').
Saline (0.2 mlmin')
Pre-infusion Post-infusion
Hepatic arterial flow 1.70 ( 0.59) 1.41 (0.36) (mlmin')
Venous inflow 5.31 ( 5.2) 6.53 (3.15) (ml min- 1)
Hepatosplanchnic flow 7.84 ( 4.42) 7.89 (3.58) (mlmin-')
Tumour:liver ratio 0.58:1 0.60:1
Systemic blood pressure 97.3 (26.7) 100.4 (39.6) (mmHg)
(Figures are median (interquartile range))
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(Goldberg et al., 1990). Histological studies have shown that
the blood vessels of tumours are undifferentiated and lack
both muscular elements and adrenergic innervation (Mattson
et al., 1978). Nevertheless, alteration of intrahepatic haemo-
dynamics may potentiate blood flow to hepatic tumour via a
secondary effect, with a redistribution of the intrahepatic
distribution of blood from high flow areas to low flow
regions.
The low rate of vasopressin infusion (0.1 mU kg-' min-')
used in this study, resulted in a systemic vasoconstriction, an
increase in systemic blood pressure, but a decrease in hepatic
arterial blood flow. Despite the reduction in hepatic arterial
flow there was an increase in tumour blood flow which is in
keeping with previous observations (Sasaki et al., 1985; Matt-
son et al., 1978) suggesting that hepatic tumour vasculature is
less responsive to pharmacological manipulation than that in
normal liver parenchyma. Furthermore, these experiments
confirm the hypothesis that vasopressin by producing an
intrahepatic vasoconstriction in liver resulting in a redistribu-
tion of arterial blood gives rise to a preferential delivery of
blood to the tumour.
The mechanism by which vasopressin produces these effect
on intrahepatic blood flow in tumour bearing rats is unclear.
Previous studies have shown that the development of liver
tumour causes marked changes in hepatic haemodynamics.
We have previously demonstrated that in animals with HSN
derived hepatic tumour, hepatic flow is unchanged, but por-
tal venous inflow is significantly reduced (Hemingway et al.,
1991). This is confirmed in these experiments with a 40%
reduction in the portal component of total liver blood flow.
The alterations in portal venous inflow may modify the
expected effects of vasopressin on hepatic haemodynamics.
Vasopressin induced changes in hepatic arterial and portal
venous flow in normal, cirrhotic and hypophysectomised
animals are dose dependent (Jenkins et al., 1985). A rate of
infusion of vasopressin (0.1 mU g'I body weight) was chosen
for this study which has been observed to produce an in-
crease in arterial pressure and portal flow with a decrease in
splanchnic vascular resistance (Jenkins et al., 1984). There-
fore, a vasopressin induced decrease in splanchnic resistance
coupled with a rise in inflow pressure may account for the
increase in portal venous inflow observed in rats with hepatic
tumour, where portal venous inflow is already decreased as a
result of the presence of tumour.
This study demonstrates that hepatic arterial vasoconstric-
tors such as vasopressin can increase effective tumour per-
fusion, thereby possibly potentiating the delivery ofcytotoxic
drugs administered regionally to the tumour. At the same
time there may be a reduction in the exposure of the normal
liver to the potentially hepatotoxic chemotherapeutic agents.
This study was funded by the Cancer Research Campaign and North
West Cancer Research Fund.
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